Global pharma major Lupin Limited on Tuesday announced the launch of the first generic version of Pred Forte (Prednisolone Acetate) Ophthalmic Suspension USP, 1% in the United States.
According to the company’s press statement, being the first generic to be approved and launched, the company is entitled to 180-day competitive generic therapy (CGT) exclusivity.
Prednisolone Acetate Ophthalmic Suspension USP, 1% is a generic equivalent of Pred Forte Ophthalmic Suspension, 1% of AbbVie, Inc. and is indicated for the treatment of steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe.
Pred Forte had estimated annual sales of USD 198 million in the U.S. (IQVIA MAT August 2024).
“The launch of Prednisolone Acetate Ophthalmic Suspension is a milestone and is aligned with our commitment to enhancing access to innovative, affordable and quality healthcare solutions,” said Vinita Gupta, CEO, Lupin. “This will strengthen our ophthalmic portfolio and will benefit patients seeking effective treatment for steroid-responsive inflammation.”
